论文部分内容阅读
目的研究腹腔热灌注化疗(continous hyperthermic peritonealperfusion chemotherapy,CHPPC)的抗癌疗效,探讨 CHPPC 的抗癌机制.方法采用人结肠癌 LoVo 细胞裸鼠腹腔种植模型(n=35),模拟结肠癌术后两个时期,即术后腹腔内散在游离癌细胞期和肉眼可见的广泛癌细胞种植期,进行腹腔灌注(MMC 0.01 g/L～0.02 g/L,10mL/min,41.5℃)治疗,观察其对癌细胞腹腔内种植的影响.结果早期 CHPPC 组的致瘤率为40%(4/10),延期 CHPPC组为60%(6/10),单纯热疗组与单纯化疗组均为80%(4/5),对照组的致瘤率为100%(5/5).生存时间(d):早期 CHPPC 组(59.4±4.9)较单纯化疗组(36.2±8.5)和单纯热疗组(35.6±9.1)明显延长(P=0.000),CHPPC 早期与延期(41.4±7.9)相比差异显著(P=0.001).结论 CHPPC 有明显的抗癌作用,早期 CHPPC 的抗癌作用显著高于延期 CHPPC 及单纯热疗、单纯化疗.实施 CHPPC 的时机是越早越好.
Objective To study the anti-cancer efficacy of intraperitoneal hyperthermic perperitoneal chemotherapy (CHPPC) and explore the anti-cancer mechanism of CHPPC. Methods Human colon cancer LoVo cells were used in nude mice (n=35) to simulate colon cancer after surgery. At the same time, intraperitoneal instillation (MMC 0.01 g/L to 0.02 g/L, 10 mL/min, 41.5°C) was performed in the intraperitoneal cavity during the period of free cancerous cells and extensive cancerous growth of the cancer cells. The effect of intraperitoneal implantation of cancer cells. Results The early onset rate of CHPPC group was 40% (4/10), 60% (6/10) in delayed CHPPC group, and 80% in simple hyperthermia group and chemotherapy alone group ( 4/5) The tumorigenic rate of the control group was 100% (5/5). Survival time (d): The early CHPPC group (59.4±4.9) was higher than the chemotherapy alone group (36.2±8.5) and the hyperthermia group (35.6). (±9.1) was significantly prolonged (P=0.000), and the difference between CHPPC early and delayed (41.4±7.9) was significant (P=0.001). Conclusions CHPPC has obvious anti-cancer effects, and the anti-cancer effect of early CHPPC is significantly higher than that of delayed CHPPC. And simply hyperthermia, chemotherapy alone. The time to implement CHPPC is as early as possible.